Roberts J Scott, Ferber Rebecca, Blacker Deborah, Rumbaugh Malia, Grill Joshua D
Department of Health Behavior & Health Education University of Michigan School of Public Health Ann Arbor Michigan USA.
Massachusetts General Hospital Harvard Medical School Boston MA USA.
Alzheimers Dement (N Y). 2021 Oct 14;7(1):e12213. doi: 10.1002/trc2.12213. eCollection 2021.
This study describes practices for disclosing individual research results to participants in Alzheimer's disease research.
An online survey of clinical core leaders at National Institutes of Health-funded Alzheimer's Disease Research Centers in the United States (response rate: 30/31, 97%) examined return of results practices across nine different types of research results.
Most centers had returned consensus research diagnoses (83%) and neuropsychological test results (73%), with fewer having shared amyloid positron emission tomography (43%), tau imaging (10%), or apolipoprotein E () genotype (7%) results. Centers reported having disclosed a mean of 3.1 types of results (standard deviation = 2.1; range 0-8). The most commonly cited reason for disclosure was to inform participants' medical decision-making (88%). Disclosure involved multiple professionals and modalities, with neurologists (87%) and in-person visits (85%) most commonplace.
Centers varied widely as to whether and how they disclosed research results. Diagnostic and cognitive test results were more commonly returned than genetic or biomarker results.
本研究描述了向阿尔茨海默病研究参与者披露个人研究结果的做法。
对美国国立卫生研究院资助的阿尔茨海默病研究中心的临床核心负责人进行在线调查(回复率:30/31,97%),调查了九种不同类型研究结果的结果反馈做法。
大多数中心反馈了共识研究诊断结果(83%)和神经心理学测试结果(73%),而分享淀粉样蛋白正电子发射断层扫描结果(43%)、tau成像结果(10%)或载脂蛋白E()基因型结果(7%)的中心较少。各中心报告平均披露了3.1种结果类型(标准差=2.1;范围0-8)。披露最常见的原因是为参与者的医疗决策提供信息(88%)。披露涉及多名专业人员和多种方式,其中神经科医生(87%)和面对面访问(85%)最为常见。
各中心在是否披露以及如何披露研究结果方面差异很大。诊断和认知测试结果比基因或生物标志物结果更常被反馈。